PHI with Neurogenic orthostatic hypotension with multiple system atrophy
How does this condition affect your private health insurance?
Multisystem Atrophy (MSA) is a rare, progressive neurodegenerative disorder affecting adults. It is characterized by severe autonomic nervous system failure, particularly orthostatic hypotension, combined with varying degrees of parkinsonism (slowed movement, rigidity), cerebellar ataxia (impaired coordination, balance), and pyramidal signs. MSA results from the degeneration of nerve cells in specific brain areas. Its insidious onset and heterogeneous presentation can make early diagnosis challenging. The condition progressively worsens, leading to significant disability and impaired quality of life due to issues like falls, speech and swallowing difficulties, and bladder dysfunction. There is currently no cure, and treatments focus on symptom management.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Symptoms typically develop insidiously over months to a few years before diagnosis.
Duration of Illness (Lifetime)
Chronic and progressively worsening, lasting until death (median survival 6-10 years from symptom onset).
Cost of Treatment (Initial)
High, involving diagnostic tests (MRI, autonomic testing), specialist consultations, and initial symptomatic medication.
Cost of Treatment (Lifetime)
Very high, encompassing ongoing specialist care, multiple symptomatic medications, extensive physical, occupational, and speech therapy, assistive devices, and eventual long-term care.
Mortality Rate
100% within 10-15 years of diagnosis, often due to complications like pneumonia or autonomic crises.
Risk of Secondary Damages
Extremely high, including severe physical disability, falls, aspiration pneumonia, urinary tract infections, severe autonomic dysfunction, depression, and significant caregiver burden.
Probability of Full Recovery
0%, as it is a progressive neurodegenerative disease with no known cure.
Underlying Disease Risk
Low, as MSA is a primary neurodegenerative disorder; however, age-related comorbidities are common, and other neurodegenerative conditions may initially be considered in the differential diagnosis.